MedTrace Logo

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

NCT06475586 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-01

No results posted yet for this study

Summary

The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response

Conditions

  • Psoriasis Vulgaris
  • Diabetes Type 2

Interventions

DRUG

Semaglutide

0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks

Sponsors & Collaborators

  • University of Banja Luka

    lead OTHER

Principal Investigators

  • Jelena Petkovic-Dabic · Faculty of Medicine Banja Luka

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2024-03-01
Completion
2024-06-10
FDA Drug
Yes

Countries

  • Bosnia and Herzegovina

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06475586 on ClinicalTrials.gov